| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4030737 | Ophthalmology | 2006 | 25 Pages |
Abstract
Continuing visual benefit was observed in patients who were randomized to receive therapy with pegaptanib in year 2 of the V.I.S.I.O.N. trials when compared with 2 years' usual care or cessation of therapy at year 1.
Related Topics
Health Sciences
Medicine and Dentistry
Ophthalmology
Authors
VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group,